“…In normal humans, NMDA receptor antagonists cause cognitive deficits analogous to those in schizophrenic patients (Javitt and Zukin, 1991;Krystal et al, 1994). In experimental animals, administration of NMDA receptor antagonists systemically or locally into the medial prefrontal cortex (mPFC) dysregulates the firing and bursting activity of pyramidal neurons (Jackson et al, 2004) and cortical glutamate release (Ceglia et al, 2004;Moghaddam and Adams, 1998;Verma and Moghaddam, 1996), and produce a range of behavioral impairments reminiscent of frontal lobe dysfunction Egerton et al, 2005;Higgins et al, 2003a;Jentsch and Roth, 1999;Le Pen et al, 2003;Murphy et al, 2005;Rodefer et al, 2005).…”